Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application
D Lombardo, MA Kiselev - Pharmaceutics, 2022 - mdpi.com
Liposomes are nano-sized spherical vesicles composed of an aqueous core surrounded by
one (or more) phospholipid bilayer shells. Owing to their high biocompatibility, chemical …
one (or more) phospholipid bilayer shells. Owing to their high biocompatibility, chemical …
In vitro release kinetics model fitting of liposomes: An insight
Liposomes are emerging cargoes for bioactive delivery owing to their widely accepted
biocompatible and biodegradable nature. It is always a challenge to control the release of …
biocompatible and biodegradable nature. It is always a challenge to control the release of …
Perspective on quantitative structure–toxicity relationship (QSTR) models to predict hepatic biotransformation of xenobiotics
Biotransformation refers to the metabolic conversion of endogenous and xenobiotic
chemicals into more hydrophilic substances. Xenobiotic biotransformation is accomplished …
chemicals into more hydrophilic substances. Xenobiotic biotransformation is accomplished …
Structural characterization of biomaterials by means of small angle X-rays and neutron scattering (SAXS and SANS), and light scattering experiments
D Lombardo, P Calandra, MA Kiselev - Molecules, 2020 - mdpi.com
Scattering techniques represent non-invasive experimental approaches and powerful tools
for the investigation of structure and conformation of biomaterial systems in a wide range of …
for the investigation of structure and conformation of biomaterial systems in a wide range of …
DNA/protein binding, molecular docking, and in vitro anticancer activity of some thioether-dipyrrinato complexes
Syntheses and characterizations of the arene ruthenium [(η6-C6H6) RuCl (4-mtdpm)](1),[(η6-
p-MeC6H4Pri) RuCl (4-mtdpm)](2), and structurally analogous rhodium/iridium complexes …
p-MeC6H4Pri) RuCl (4-mtdpm)](2), and structurally analogous rhodium/iridium complexes …
Synthesis, antiproliferative activity and apoptosis-promoting effects of arene ruthenium (II) complexes with N, O chelating ligands
N Mohan, MKM Subarkhan, R Ramesh - Journal of Organometallic …, 2018 - Elsevier
New half sandwich arene ruthenium (II) complexes of the type [Ru (arene) Cl (L)](where
arene= benzene and p-cymene, L= thiophene benzhydrazone ligands) have been …
arene= benzene and p-cymene, L= thiophene benzhydrazone ligands) have been …
DNA binding and anti-cancer activity of redox-active heteroleptic piano-stool Ru (II), Rh (III), and Ir (III) complexes containing 4-(2-methoxypyridyl) …
The synthesis of four novel heteroleptic dipyrrinato complexes [(η6-arene) RuCl (2-
pcdpm)](η6-arene= C6H6, 1; C10H14, 2) and [(η5-C5Me5) MCl (2-pcdpm)](M= Rh, 3; Ir, 4) …
pcdpm)](η6-arene= C6H6, 1; C10H14, 2) and [(η5-C5Me5) MCl (2-pcdpm)](M= Rh, 3; Ir, 4) …
Influence of lipid composition, pH, and temperature on physicochemical properties of liposomes with curcumin as model drug
B Roy, P Guha, R Bhattarai, P Nahak… - Journal of oleo …, 2016 - jstage.jst.go.jp
The physicochemical properties of large unilamellar vesicles (LUVs) were assessed with
respect to lipid composition, pH, time, and temperature by monitoring their size, zeta …
respect to lipid composition, pH, time, and temperature by monitoring their size, zeta …
Synthesis, structure, DNA/protein binding, and anticancer activity of some half-sandwich cyclometalated Rh (III) and Ir (III) complexes
S Mukhopadhyay, RK Gupta, RP Paitandi… - …, 2015 - ACS Publications
The Schiff base ligands benzylidene (4-tert-butylphenyl) amine 4-methyl ester (L1),(4-
nitrobenzylidene)(4-tert-butylphenyl) amine (L2), and (4-cyanobenzylidene)(4-tert …
nitrobenzylidene)(4-tert-butylphenyl) amine (L2), and (4-cyanobenzylidene)(4-tert …
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes
MA Farooq, H Xinyu, A Jabeen, A Ahsan… - Colloids and Surfaces B …, 2021 - Elsevier
Vorinostat (VOR) is known as one of the histone deacetylase inhibitors (HDACi) for cancer
treatment, and the FDA approves it for cutaneous T cell lymphoma therapy. Poor solubility …
treatment, and the FDA approves it for cutaneous T cell lymphoma therapy. Poor solubility …